Cell mutations can increase brain aneurisms

Using innovating DNA analysis techniques, researchers at UNIGE and at the University of Toronto identified the underlying cause of brain arteriovenous malformations, and provide insight into potential therapies.

Frontal view of a cerebral angiography. The cerebral angiography consists of injecting the dye into the arterial circulation of the brain followed by a series of x-ray images. The dye takes about 4-5 seconds to go from arteries to capillaries and finally to the veins in the brain.
Frontal view of a cerebral angiography. The cerebral angiography consists of injecting the dye into the arterial circulation of the brain followed by a series of x-ray images. The dye takes about 4-5 seconds to go from arteries to capillaries and finally to the veins in the brain.

Sporadic arteriovenous malformations in the brain – a severe type of brain aneurysms – is a leading cause of hemorrhagic stroke in young adults and children. Affecting about 15 in 100 000 people, it consists of an abnormal development of the brain vascular system, potentially occurring during fetal life.

By identifying its origin – a somatic mutation in endothelial cells that form the inner layer of blood vessels – researchers at the University of Geneva (UNIGE), Switzerland, and at the University of Toronto, Canada, show the impact of a somatic mutation and open some avenues to improved treatment. Their results can be read in the New England Journal of Medicine.

Brain arteriovenous malformations (BAVM) are a collection of anomalous vessels of the brain that are thought to develop during fetal life or early childhood. They consist of morphologically abnormal and direct connections between arteries and veins, where capillaries (the smallest type of blood vessels) are missing. When the pressure increases too much, BAVMs can rupture, causing a massive and potentially lethal brain hemorrhage.

“BAVM is primarily of sporadic nature, meaning that there is not a predisposition in families. This, however, does not mean that there is no genetic basis to it”, explains Sergey Nikolaev, a researcher in Bioinformatics at UNIGE Faculty of Medicine, a biologist at the genomics consultation of the Geneva University Hospitals (HUG) and the article’s first author. “We, therefore, hypothesized that it may be associated with a DNA de novo mutation in brain cells, a mutation which is not present in the germinal cells, thus not inherited.”

Another disorder that causes similar lesions, the Capillary malformation-arteriovenous malformation syndrome (CM-AVM), is due to an inherited mutation of the regulator of the KRAS gene (a gene essential to cell signaling in many tissues). Drawing a parallel, the scientists decided to look for brain malformations of BAVM patients that would have the mutation in the same pathway.

They collected 26 samples from BAVM patients in Toronto, on which they performed DNA exome sequencing, looking for somatic mutations. “KRAS is a gene coding for a protein that performs. We found in some patients a KRAS mutation usually associated with certain types of cancer, such as melanoma. It gave us a first hint of where to look”, recounts Jason Fish of the University of Toronto, a study co-author.

The scientists used a new technology, called “droplet digital PCR”, which allows for a more precise analysis of DNA molecules. Thanks to it, they were able to identify mutations affecting only a very small proportion of cells present in the brain, the endothelial cells that form the inner layer of blood vessels. Out of their 72 samples from Toronto, Canada and Kuopio, Finland, 45 (62%) turned out positive for KRAS mutation.

KRAS activates pathways in the endothelial cells which can drive vascular growth. When mutated, it dysregulates angiogenesis and vascular remodeling. When these pathways are activated, the diameter of the vessel increases; consequently, arteries are misconnected with veins, causing an aneurism that can rupture at any time.

“Our results show a very likely cause of brain arteriovenous malformations,” points out study last author Ivan Radovanovic, professor of neurosurgery at the University of Toronto, Canada.

“To understand what causes these malformations is a significant advance and it opens some avenues and hope for maybe improving their treatment, adding some options.” Among them, KRAS inhibitors could be tested for their ability to reduce the size of aneurism.

“Our study also suggests a context-dependent role for somatic KRAS mutations: arteriovenous malformations of the brain are not associated with cancer, and neither is endometriosis, where somatic activating KRAS mutations were also found in a previous study”, concludes Sergey Nikolaev.